drugset / Trial / NCT01028248
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine whether ranibizumab (Lucentis) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
Timeline
- Start
- 2010-01
- Primary completion
- 2012-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |